Intracranial Hemorrhage: Withhold avapritinib for grade 1 or 2 reactions (subdural hematoma, intracranial hemorrhage, and cerebral hemorrhage) until resolution and then resume at a reduced dose. Permanently discontinue for recurrent grade 1 or 2 reactions or first occurrence of grade 3 or 4 reactions.
- TRADE NAME: Ayvakit (Blueprint Medicines)
- INDICATIONS: Treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
- CLASS: Tyrosine kinase inhibitor
- HALF-LIFE: 32–57 hours
- FDA APPROVAL DATE: 01/09/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducer, CYP3A inhibitor, Efavirenz, Fluconazole, Itraconazole - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
